Summary:

- The article discusses the ongoing search for the next breakthrough in immuno-oncology, following the success of Keytruda (pembrolizumab), a monoclonal antibody that has transformed the treatment of various types of cancer.

- It explores the current state of immuno-oncology research, highlighting the efforts of pharmaceutical companies and researchers to develop new immunotherapies that can build upon the success of Keytruda and provide additional treatment options for cancer patients.

- The article delves into the challenges and opportunities in the field, including the exploration of combination therapies, the development of novel targets and mechanisms of action, and the need to address the limitations of existing immunotherapies.